Figure 1. Adjusted rates of estimated glomerular filtration rate (eGFR) dip in the first 6 months among users of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) and other antihyperglycemics.

Adjusted rates of eGFR dip >10% to 20%, >20% to 30%, and >30% in the SGLT2i group (blue) and the other antihyperglycemic group (red); model was adjusted for covariates at treatment initiation. Error bars represent 95% CIs.